{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:50:25Z","timestamp":1789026625837,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T00:00:00Z","timestamp":1631059200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T00:00:00Z","timestamp":1631059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["R01 AA022886"],"award-info":[{"award-number":["R01 AA022886"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["U10 AA013566"],"award-info":[{"award-number":["U10 AA013566"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["1IK2HX003007"],"award-info":[{"award-number":["1IK2HX003007"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["K12HS026370"],"award-info":[{"award-number":["K12HS026370"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"crossref","award":["UG3DA044831"],"award-info":[{"award-number":["UG3DA044831"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"crossref","award":["UG1DA015815"],"award-info":[{"award-number":["UG1DA015815"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA040471"],"award-info":[{"award-number":["R01DA040471"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA047347"],"award-info":[{"award-number":["R01DA047347"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"national center for advancing translational sciences","doi-asserted-by":"publisher","award":["UL1TR003017"],"award-info":[{"award-number":["UL1TR003017"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s10461-021-03452-0","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T09:03:06Z","timestamp":1631091786000},"page":"975-985","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder Among Patients With and Without HIV"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4789-4390","authenticated-orcid":false,"given":"Jessica J.","family":"Wyse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen A.","family":"McGinnis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Jennifer","family":"Edelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Manhapra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Fiellin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent A.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Todd","family":"Korthuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy J.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Oldfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie R.","family":"Gaither","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsha S.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Skanderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Declan T.","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendall","family":"Bryant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Crystal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy C.","family":"Justice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Kraemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,8]]},"reference":[{"key":"3452_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002207.pub4","author":"RP Mattick","year":"2014","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Syst Rev. 2014. https:\/\/doi.org\/10.1002\/14651858.CD002207.pub4.","journal-title":"Cochrane Database of Syst Rev."},{"key":"3452_CR2","volume-title":"Medications for Opioid Use Disorder Save Lives","author":"National Academies of Sciences, Engineering, and Medicine","year":"2019","unstructured":"National Academies of Sciences, Engineering, and Medicine. Medications for Opioid Use Disorder Save Lives. Washington, DC: National Academies Press; 2019."},{"key":"3452_CR3","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1136\/bmj.j1550","volume":"357","author":"L Sordo","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:1550.","journal-title":"BMJ"},{"issue":"5","key":"3452_CR4","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1377\/hlthaff.2019.01085","volume":"39","author":"H Samples","year":"2020","unstructured":"Samples H, Williams AR, Crystal S, Olfson M. Impact of long-term buprenorphine treatment on adverse health care outcomes in Medicaid: the impact of longer treatment on health care outcomes for opioid use disorder within a key population of Medicaid enrollees. Health Aff. 2020;39(5):747\u201355.","journal-title":"Health Aff"},{"key":"3452_CR5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.drugalcdep.2014.03.006","volume":"139","author":"EJ Edelman","year":"2014","unstructured":"Edelman EJ, Chantarat T, Caffrey S, et al. The impact of buprenorphine\/naloxone treatment on HIV risk behaviors among HIV-infected, opioid-dependent patients. Drug Alcohol Depend. 2014;139:79\u201385.","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"3452_CR6","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1111\/j.1360-0443.2008.02323.x","volume":"103","author":"P Roux","year":"2008","unstructured":"Roux P, Carrieri MP, Villes V, et al. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study. Addiction. 2008;103(11):1828\u201336.","journal-title":"Addiction"},{"key":"3452_CR7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jsat.2017.01.015","volume":"75","author":"BL Norton","year":"2017","unstructured":"Norton BL, Beitin A, Glenn M, DeLuca J, Litwin AH, Cunningham CO. Retention in buprenorphine treatment is associated with improved HCV care outcomes. J Subst Abuse Treat. 2017;75:38\u201342.","journal-title":"J Subst Abuse Treat"},{"key":"3452_CR8","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1097\/QAI.0b013e31820a8226","volume":"56","author":"L Weiss","year":"2011","unstructured":"Weiss L, Netherland J, Egan JE, et al. Integration of buprenorphine\/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative. J Acquir Immune Defic Syndr. 2011;56:S68\u201375.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9","key":"3452_CR9","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1093\/aje\/kwy092","volume":"187","author":"CR Lesko","year":"2018","unstructured":"Lesko CR, Keil AP, Moore RD, Chander G, Fojo AT, Lau B. Measurement of current substance use in a cohort of HIV-infected persons in continuity HIV care, 2007\u20132015. Am J Epidemiol. 2018;187(9):1970\u20139.","journal-title":"Am J Epidemiol"},{"issue":"5","key":"3452_CR10","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1097\/QAD.0000000000002125","volume":"33","author":"BJ Oldfield","year":"2019","unstructured":"Oldfield BJ, Mu\u00f1oz N, McGovern MP, et al. Integration of care for HIV and opioid use disorder. AIDS. 2019;33(5):873\u201384.","journal-title":"AIDS"},{"issue":"Suppl 1","key":"3452_CR11","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1097\/QAI.0b013e318209751e","volume":"56","author":"FL Altice","year":"2011","unstructured":"Altice FL, Bruce RD, Lucas GM, et al. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine\/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S22.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"3452_CR12","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s11904-012-0134-8","volume":"9","author":"MC Binford","year":"2012","unstructured":"Binford MC, Kahana SY, Altice FL. A systematic review of antiretroviral adherence interventions for HIV-infected people who use drugs. Curr HIV\/AIDS Rep. 2012;9(4):287\u2013312.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"9","key":"3452_CR13","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1086\/630209","volume":"49","author":"P Roux","year":"2009","unstructured":"Roux P, Carrieri MP, Cohen J, et al. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment. Clin Infect Dis. 2009;49(9):1433\u201340.","journal-title":"Clin Infect Dis"},{"key":"3452_CR14","doi-asserted-by":"publisher","first-page":"107670","DOI":"10.1016\/j.drugalcdep.2019.107670","volume":"206","author":"JW Adams","year":"2020","unstructured":"Adams JW, Marshall BD, Salleh NA, Barrios R, Nolan S, Milloy MJ. Receipt of opioid agonist treatment halves the risk of HIV-1 RNA viral load rebound through improved ART adherence for HIV-infected women who use illicit drugs. Drug Alcohol Depend. 2020;206:107670.","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"3452_CR15","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/add.13270","volume":"111","author":"W Lo-Ciganic","year":"2016","unstructured":"Lo-Ciganic W, Gellad WF, Gordon AJ, et al. Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization. Addiction. 2016;111(5):892\u2013902.","journal-title":"Addiction"},{"issue":"2","key":"3452_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1176\/appi.ajp.2019.19060612","volume":"177","author":"AR Williams","year":"2020","unstructured":"Williams AR, Samples H, Crystal S, Olfson M. Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder. Am J Psychiatry. 2020;177(2):117\u201324.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"3452_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","volume":"35","author":"C Timko","year":"2016","unstructured":"Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C. Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis. 2016;35(1):22\u201335.","journal-title":"J Addict Dis"},{"issue":"5","key":"3452_CR18","doi-asserted-by":"publisher","first-page":"e0232086","DOI":"10.1371\/journal.pone.0232086","volume":"15","author":"AM O\u2019Connor","year":"2020","unstructured":"O\u2019Connor AM, Cousins G, Durand L, Barry J, Boland F. Retention of patients in opioid substitution treatment: a systematic review. PLoS ONE. 2020;15(5):e0232086.","journal-title":"PLoS ONE"},{"issue":"6","key":"3452_CR19","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/ajad.12553","volume":"26","author":"A Manhapra","year":"2017","unstructured":"Manhapra A, Petrakis I, Rosenheck R. Three-year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration. Am J Addict. 2017;26(6):572\u201380.","journal-title":"Am J Addict"},{"key":"3452_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jsat.2016.12.010","volume":"74","author":"ZM Weinstein","year":"2017","unstructured":"Weinstein ZM, Kim HW, Cheng DM, et al. Long-term retention in office based opioid treatment with buprenorphine. J Subst Abuse Treat. 2017;74:65\u201370.","journal-title":"J Subst Abuse Treat"},{"key":"3452_CR21","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1097\/01.mlr.0000223670.00890.74","volume":"2006","author":"SL Fultz","year":"2006","unstructured":"Fultz SL, Skanderson M, Mole LA, et al. Development and verification of a \u201cvirtual\u201d cohort using the National VA Health Information System. Med Care. 2006;2006:S25\u201330.","journal-title":"Med Care"},{"issue":"2","key":"3452_CR22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1080\/08897077.2018.1452327","volume":"39","author":"JJ Wyse","year":"2018","unstructured":"Wyse JJ, Gordon AJ, Dobscha SK, et al. Medications for opioid use disorder in the Department of Veterans Affairs (VA) health care system: historical perspective, lessons learned, and next steps. Subst Abuse. 2018;39(2):139\u201344.","journal-title":"Subst Abuse"},{"key":"3452_CR23","doi-asserted-by":"publisher","first-page":"108509","DOI":"10.1016\/j.jsat.2021.108509","volume":"132","author":"AJ Kennedy","year":"2021","unstructured":"Kennedy AJ, McGinnis KA, Merlin JS, et al. Impact of intensity of behavioral treatment, with or without medication treatment, for opioid use disorder on HIV outcomes in persons with HIV. J Subst Abuse Treat. 2021;132:108509.","journal-title":"J Subst Abuse Treat"},{"key":"3452_CR24","unstructured":"Substance Abuse and Mental Health Services. Federal Guidelines for Opioid Treatment Programs. HHS Publication No. (SMA) PEP15-FEDGUIDEOTP. 2015 December. https:\/\/store.samhsa.gov\/sites\/default\/files\/d7\/priv\/pep15-fedguideotp.pdf. Accessed August 20, 2020."},{"issue":"7","key":"3452_CR25","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1097\/MLR.0000000000000727","volume":"55","author":"B Saloner","year":"2017","unstructured":"Saloner B, Daubresse M, Caleb AG. Patterns of buprenorphine-naloxone treatment for opioid use disorder in a multistate population. Med Care. 2017;55(7):669\u201376.","journal-title":"Med Care"},{"key":"3452_CR26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jsat.2019.11.002","volume":"109","author":"BJ Oldfield","year":"2020","unstructured":"Oldfield BJ, McGinnis KA, Edelman EJ, et al. Predictors of initiation of and retention on medications for alcohol use disorder among people living with and without HIV. J Subst Abuse Treat. 2020;109:14\u201322.","journal-title":"J Subst Abuse Treat"},{"key":"3452_CR27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.drugalcdep.2019.01.038","volume":"198","author":"JJ Wyse","year":"2019","unstructured":"Wyse JJ, Robbins JL, McGinnis KA, et al. Predictors of timely opioid agonist treatment initiation among veterans with and without HIV. Drug Alcohol Depend. 2019;198:70\u20135.","journal-title":"Drug Alcohol Depend"},{"key":"3452_CR28","doi-asserted-by":"publisher","first-page":"108272","DOI":"10.1016\/j.drugalcdep.2020.108272","volume":"217","author":"KA McGinnis","year":"2020","unstructured":"McGinnis KA, Skanderson M, Edelman EJ, et al. Impact of behavioral and medication treatment for alcohol use disorder on changes in HIV-related outcomes among patients with HIV: a longitudinal analysis. Drug Alcohol Depend. 2020;217:108272.","journal-title":"Drug Alcohol Depend"},{"key":"3452_CR29","volume-title":"Stata Statistical Software: Release 14","author":"StataCorp,","year":"2015","unstructured":"StataCorp. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP; 2015."},{"key":"3452_CR30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jsat.2018.09.001","volume":"95","author":"H Samples","year":"2018","unstructured":"Samples H, Williams AR, Olfson M, Crystal S. Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees. J Subst Abuse Treat. 2018;95:9\u201317.","journal-title":"J Subst Abuse Treat"},{"key":"3452_CR31","first-page":"1","volume":"2020","author":"N Brunet","year":"2020","unstructured":"Brunet N, Moore DT, Lendvai Wischik D, Mattocks KM, Rosen MI. Increasing buprenorphine access for veterans with opioid use disorder in rural clinics using telemedicine. Subst Abuse. 2020;2020:1\u20138.","journal-title":"Subst Abuse"},{"issue":"3","key":"3452_CR32","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/08897077.2020.1787299","volume":"41","author":"AJ Gordon","year":"2020","unstructured":"Gordon AJ, Drexler K, Hawkins EJ, et al. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities. Subst Abuse. 2020;41(3):275\u201382.","journal-title":"Subst Abuse"},{"key":"3452_CR33","unstructured":"U.S. Department of Veterans Affairs. VHA DIRECTIVE 1304. National Human Immunodeficiency Virus Program. Washington, DC: Veterans Health Administration; 2019. Available from: https:\/\/www.va.gov\/vhapublications\/ViewPublication.asp?pub_ID=3056."},{"issue":"2","key":"3452_CR34","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/jcop.21673","volume":"43","author":"T Ghose","year":"2015","unstructured":"Ghose T, Gordon AJ, Metraux S, et al. The association between HIV status and homelessness among veterans in care. J Community Psychol. 2015;43(2):189\u201398.","journal-title":"J Community Psychol"},{"issue":"7","key":"3452_CR35","doi-asserted-by":"publisher","first-page":"499","DOI":"10.7326\/M17-1073","volume":"167","author":"PS Belperio","year":"2017","unstructured":"Belperio PS, Chartier M, Ross DB, Alaigh P, Shulkin D. Curing hepatitis C virus infection: best practices from the US Department of Veterans Affairs. Ann Intern Med. 2017;167(7):499\u2013504.","journal-title":"Ann Intern Med"},{"issue":"1","key":"3452_CR36","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/add.12333","volume":"109","author":"Y-I Hser","year":"2014","unstructured":"Hser Y-I, Saxon AJ, Huang D, et al. Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial. Addiction. 2014;109(1):79\u201387.","journal-title":"Addiction"},{"issue":"7","key":"3452_CR37","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1111\/j.1360-0443.2009.02627.x","volume":"104","author":"J Bell","year":"2009","unstructured":"Bell J, Trinh L, Butler B, Randall D, Rubin G. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction. 2009;104(7):1193\u2013200.","journal-title":"Addiction"},{"issue":"6","key":"3452_CR38","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1111\/j.1360-0443.2009.02539.x","volume":"104","author":"PG Barnett","year":"2009","unstructured":"Barnett PG. Comparison of costs and utilization among buprenorphine and methadone patients. Addiction. 2009;104(6):982\u201392.","journal-title":"Addiction"},{"issue":"3","key":"3452_CR39","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1080\/08897077.2018.1509251","volume":"39","author":"H Valenstein-Mah","year":"2018","unstructured":"Valenstein-Mah H, Hagedorn H, Kay CL, Christopher ML, Gordon AJ. Underutilization of the current clinical capacity to provide buprenorphine treatment for opioid use disorders within the Veterans Health Administration. Subst Abuse. 2018;39(3):286\u20138.","journal-title":"Subst Abuse"},{"issue":"1","key":"3452_CR40","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/ADM.0000000000000739","volume":"15","author":"B Chan","year":"2020","unstructured":"Chan B, Gean E, Arkhipova-Jenkins I, et al. Retention strategies for medications for opioid use disorder in adults: a rapid evidence review. J Addict Med. 2020;15(1):74\u201384.","journal-title":"J Addict Med"}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-021-03452-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-021-03452-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-021-03452-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T14:16:14Z","timestamp":1644675374000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10461-021-03452-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,8]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["3452"],"URL":"https:\/\/doi.org\/10.1007\/s10461-021-03452-0","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"value":"1090-7165","type":"print"},{"value":"1573-3254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,8]]},"assertion":[{"value":"26 August 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose. The content of this article is solely the responsibility of the authors and does not represent the official views of the Department of Veterans Affairs or the Agency for Healthcare Research and Quality.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the Institutional Review Boards of the University of Pittsburgh, VA Pittsburgh Healthcare System and VA Connecticut Healthcare System and the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}